Skip to main content

Feder Julie B's Form 4 filing

Aura Biosciences, Inc. (AURA) · filed Oct 21, 2024

Accession no.
0000950170-24-116029
Filed
Oct 21, 2024
Trade date
Oct 18, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $302.3K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Feder Julie BCIK 0001710237Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 18, 2024Common StockMOption exerciseAcquired+17,500$2.74+$47,950151,776Direct
Oct 18, 2024Common StockMOption exerciseAcquired+2,631$4.25+$11,181.75154,407Direct
Oct 18, 2024Common StockMOption exerciseAcquired+5,000$5.48+$27,400159,407Direct
Oct 18, 2024Common StockSSaleDisposed−25,131$12.03F2−$302,325.93134,276Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 18, 2024Common StockMOption exerciseDisposed−17,500$0.00$068,257Direct
Oct 18, 2024Common StockMOption exerciseDisposed−2,631$0.00$032,359Direct
Oct 18, 2024Common StockMOption exerciseDisposed−5,000$0.00$0120,547Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24.1 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)